|
Volumn 10, Issue 4, 2009, Pages 309-310
|
Surrogate endpoints in head and neck cancer
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ANTINEOPLASTIC AGENT;
CANCER CHEMOTHERAPY;
CANCER CONTROL;
CLINICAL TRIAL;
DISEASE FREE SURVIVAL;
DRUG APPROVAL;
DRUG EFFICACY;
HEAD AND NECK CANCER;
HEAD AND NECK SURGERY;
HUMAN;
LETTER;
OUTCOME ASSESSMENT;
OVERALL SURVIVAL;
PRIORITY JOURNAL;
QUALITY OF LIFE;
COMBINED MODALITY THERAPY;
ENDPOINT DETERMINATION;
HEAD AND NECK NEOPLASMS;
HUMANS;
NEOPLASM RECURRENCE, LOCAL;
SURVIVAL RATE;
TUMOR MARKERS, BIOLOGICAL;
|
EID: 63149103474
PISSN: 14702045
EISSN: None
Source Type: Journal
DOI: 10.1016/S1470-2045(09)70044-0 Document Type: Letter |
Times cited : (3)
|
References (4)
|